Flora Growth Corp. announced the formation of Flora Lab, a consolidated manufacturing division that will be comprised of the recently acquired Quipropharma Lab and the strategic business combination of its two medical-focused divisions, Cronomed and Breeze Laboratory. The newly formed division is underpinned by Quipropharma Lab, a modern 16,000-square-ft manufacturing facility and holds multiple GMP certifications with a diversified portfolio with over 190 products and 63 OTC products registered and licensed with INVIMA (FDA-equivalent in Colombia). With both branded products and a suite of wholesale white-label clients, Flora Lab is expected to serve as the manufacturing centre for Flora. The addition of the new manufacturing certifications and production capacity from Quipropharma when combined with Breeze and Cronomed’s existing distribution network is expected to increase Flora’s overall revenue potential. Looking forward, the division will be focused on expanding its 1,500+ distribution channels and developing new cannabinoid and non-cannabinoid containing products to sell to its network of pharmacies and wholesale clients.Some highlights from Quipropharma Lab include: The laboratory is a modern 16,000-square-ft facility. The laboratory holds 2 GMP certifications: Phytotherapeutics. Dietary Supplements. The laboratory has the capability to produce CBD-containing products. The laboratory holds 18 domestic clients and sells branded products along with white-label products.